Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
FAST-ACTING INGREDIENT RELEASE PERFORMIX SST BURN is formulated as a liquid to target fast-acting release functionality
This reduction in SCFAs may play a crucial role in the ENS changes and gut dysmotility seen in PD
Synergistic Effect : The combined action on both GLP-1 and GIP receptors is speculated to produce a synergistic effect that could result in greater glycemic control and weight reduction than targeting either receptor alone, based on the positive clinical trial outcomes noted with the first approved dual GLP-1/GIP receptor agonist, tirzepatide
Rachel Halverson, RN, CDCES, NC-BC explains that metformin is typically considered the first-line of treatment for T2D and is widely used due to its long history of effectiveness, safety, and low cost. It works primarily by reducing glucose production in the liver and improving the bodys insulin sensitivity
